| PH |
Report |
Adjusted EPS |
BEAT |
pred ~$8.40 vs. cons $8.27 |
MEDIUM |
| PH |
Report |
Revenue |
IN-LINE |
pred ~$5.61B vs. cons $5.573B |
MEDIUM |
| PH |
Report |
Organic growth |
BEAT |
pred ~4.7% vs. cons 4.45% |
MEDIUM |
| PH |
Guide |
FY2027 adjusted EPS |
BETTER |
guide ~$34.50 vs. cons $34.07 |
MEDIUM |
| PH |
Guide |
FY2027 revenue |
UNCHANGED |
guide ~$22.8B vs. cons $22.62B |
MEDIUM |
| PH |
Guide |
FY2027 organic growth |
BETTER |
guide ~6.0% vs. cons 5.78% |
MEDIUM |
| PH |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
LOW |
| PH |
Return |
5-day cumulative residual |
+4.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — FY2027 estimates move higher |
LOW |